{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T18:52:45Z","timestamp":1649011965965},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00120-018-0628-0","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T07:41:57Z","timestamp":1523518917000},"page":"679-685","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiochemotherapie beim Harnblasenkarzinom"],"prefix":"10.1007","volume":"57","author":[{"given":"N.","family":"Tselis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. J.","family":"Prott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"628_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ijrobp.2013.11.227","volume":"88","author":"S Aluwini","year":"2014","unstructured":"Aluwini S, van Rooij PH, Kirkels WJ et al (2014) Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: long-term results. Int J Radiat Oncol Biol Phys 88:611\u2013617","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"628_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/(SICI)1097-0142(19960901)78:5<1089::AID-CNCR20>3.0.CO;2-Y","volume":"78","author":"O Caffo","year":"1996","unstructured":"Caffo O, Fellin G, Graffer U, Luciani L (1996) Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a\u00a0self-administered questionnaire. Cancer 78:1089\u20131097","journal-title":"Cancer"},{"key":"628_CR3","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","volume":"14","author":"CM Coppin","year":"1996","unstructured":"Coppin CM, Gospodarowicz MK, James K et\u00a0al (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J\u00a0Clin Oncol 14:2901\u20132907","journal-title":"J Clin Oncol"},{"key":"628_CR4","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1002\/cncr.20654","volume":"101","author":"DT Danesi","year":"2004","unstructured":"Danesi DT, Arcangeli G, Cruciani E et\u00a0al (2004) Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer 101:2540\u20132548","journal-title":"Cancer"},{"key":"628_CR5","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","volume":"27","author":"JA Efstathiou","year":"2009","unstructured":"Efstathiou JA, Bae K, Shipley WU et al (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J\u00a0Clin Oncol 27:4055\u20134061","journal-title":"J Clin Oncol"},{"key":"628_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","volume":"61","author":"JA Efstathiou","year":"2012","unstructured":"Efstathiou JA, Spiegel DY, Shipley WU et al (2012) Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 61:705\u2013711","journal-title":"Eur Urol"},{"key":"628_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","volume":"57","author":"MP Hagan","year":"2003","unstructured":"Hagan MP, Winter KA, Kaufman DS et al (2003) RTOG 97-06: initial report of a\u00a0phase I\u2011II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57:665\u2013672","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"628_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.radonc.2004.11.003","volume":"75","author":"A Horwich","year":"2005","unstructured":"Horwich A, Dearnaley D, Huddart R et\u00a0al (2005) A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol 75:34\u201343","journal-title":"Radiother Oncol"},{"key":"628_CR9","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","volume":"28","author":"PJ Hoskin","year":"2010","unstructured":"Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI (2010) Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J\u00a0Clin Oncol 28:4912\u20134918","journal-title":"J Clin Oncol"},{"key":"628_CR10","first-page":"319a","volume":"16","author":"M Housset","year":"1997","unstructured":"Housset M, Dufour B, Maulard-Durdux C et al (1997) Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy for invasive bladder cancer. Proc Am Soc Clin Oncol 16:319a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"628_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1464-410X.2010.09537.x","volume":"106","author":"RA Huddart","year":"2010","unstructured":"Huddart RA, Hall E, Lewis R, Birtle A (2010) SPARE Trial Management Group. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int 106:753\u2013755","journal-title":"BJU Int"},{"key":"628_CR12","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James ND, Hussain SA, Hall E et al (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N\u00a0Engl J Med 366:1477\u20131488","journal-title":"N Engl J Med"},{"key":"628_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"DS Kaufman","year":"2000","unstructured":"Kaufman DS, Winter KA, Shipley WU et al (2000) The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I\/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5\u2011fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5:471\u2013476","journal-title":"Oncologist"},{"key":"628_CR14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","volume":"73","author":"DS Kaufman","year":"2009","unstructured":"Kaufman DS, Winter KA, Shipley WU et al (2009) Phase I\u2011II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73:833\u2013837","journal-title":"Urology"},{"key":"628_CR15","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","volume":"35","author":"GS Kulkarni","year":"2017","unstructured":"Kulkarni GS, Hermanns T, Wei Y et al (2017) Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a\u00a0multidisciplinary bladder cancer clinic. J\u00a0Clin Oncol 35:2299\u20132305","journal-title":"J Clin Oncol"},{"key":"628_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijrobp.2009.10.038","volume":"79","author":"JL Lagrange","year":"2011","unstructured":"Lagrange JL, Bascoul-Mollevi C, Geoffrois L et al (2011) Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a\u00a0multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys 79:172\u2013178","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"628_CR17","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"Mak RH, Hunt D, Shipley WU et al (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a\u00a0pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J\u00a0Clin Oncol 32:3801\u20133809","journal-title":"J Clin Oncol"},{"key":"628_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"T Mitin","year":"2013","unstructured":"Mitin T, Hunt D, Shipley WU et al (2013) Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a\u00a0randomised multicentre phase 2 trial. Lancet Oncol 14:863\u2013872","journal-title":"Lancet Oncol"},{"key":"628_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","volume":"66","author":"G Ploussard","year":"2014","unstructured":"Ploussard G, Efstathiou JA, Herr HH et al (2014) Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a\u00a0systematic review. Eur Urol 66:120\u2013137","journal-title":"Eur Urol"},{"key":"628_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14109","author":"CR Ritch","year":"2017","unstructured":"Ritch CR, Balise R, Prakash NS et al (2017) Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. BJU Int. \n                    https:\/\/doi.org\/10.1111\/bju.14109","journal-title":"BJU Int"},{"key":"628_CR21","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/JCO.2006.07.6729","volume":"24","author":"C R\u00f6del","year":"2006","unstructured":"R\u00f6del C, Weiss C, Sauer R (2006) Trimodality treatment and selective organ preservation for bladder cancer. J\u00a0Clin Oncol 24:5536\u20135544","journal-title":"J Clin Oncol"},{"key":"628_CR22","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","volume":"20","author":"C R\u00f6del","year":"2002","unstructured":"R\u00f6del C, Grabenbauer GG, Kuhn R et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J\u00a0Clin Oncol 20:3061\u20133071","journal-title":"J Clin Oncol"},{"key":"628_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.03.038","author":"T Seisen","year":"2017","unstructured":"Seisen T, Sun M, Lipsitz SR et al (2017) Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder. Eur Urol. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2017.03.038","journal-title":"Eur Urol"},{"key":"628_CR24","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","volume":"16","author":"WU Shipley","year":"1998","unstructured":"Shipley WU, Winter KA, Kaufman DS et al (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J\u00a0Clin Oncol 16:3576\u20133583","journal-title":"J Clin Oncol"},{"key":"628_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/0360-3016(93)90306-G","volume":"25","author":"W Tester","year":"1993","unstructured":"Tester W, Porter A, Asbell S et al (1993) Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25:783\u2013790","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"628_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/JCO.1996.14.1.119","volume":"14","author":"W Tester","year":"1996","unstructured":"Tester W, Caplan R, Heaney J et\u00a0al (1996) Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J\u00a0Clin Oncol 14:119\u2013126","journal-title":"J Clin Oncol"},{"key":"628_CR27","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","volume":"82","author":"MA Tunio","year":"2012","unstructured":"Tunio MA, Hashmi A, Qayyum A et al (2012) Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys 82:e457\u2013462","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"628_CR28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.radonc.2009.04.020","volume":"93","author":"E Steen-Banasik Van der","year":"2009","unstructured":"Van der Steen-Banasik E, Ploeg M, Witjes JA et al (2009) Brachytherapy versus cystectomy in solitary bladder cancer: a\u00a0case control, multicentre, East-Netherlands study. Radiother Oncol 93:352\u2013357","journal-title":"Radiother Oncol"},{"key":"628_CR29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ijrobp.2016.11.056","volume":"97","author":"V Vashistha","year":"2017","unstructured":"Vashistha V, Wang H, Mazzone A et al (2017) Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a\u00a0systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 97:1002\u20131020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"628_CR30","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.ijrobp.2007.08.007","volume":"70","author":"C Weiss","year":"2008","unstructured":"Weiss C, Wittlinger M, Engehausen DG et al (2008) Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 70:1502\u20131506","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"628_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.radonc.2009.09.018","volume":"93","author":"M Wittlinger","year":"2009","unstructured":"Wittlinger M, R\u00f6del CM, Weiss C et al (2009) Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol 93:358\u2013363","journal-title":"Radiother Oncol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-018-0628-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-018-0628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-018-0628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T23:18:48Z","timestamp":1555024728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-018-0628-0"}},"subtitle":["Ein Update"],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["628"],"URL":"https:\/\/doi.org\/10.1007\/s00120-018-0628-0","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]},"assertion":[{"value":"12 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Tselis, F.J.\u00a0Prott, O.\u00a0Ott, C.\u00a0Weiss und C.\u00a0R\u00f6del geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}